Illuminare Biotechnologies has appointed biopharmaceutical executive Brian Longstreet as chief executive officer, effective June 1, 2026, as the clinical-stage company prepares to advance its lead nerve visualization therapy into Phase 2 clinical development and moves closer to commercialization.
Longstreet succeeds Walter Greenblatt, who transitions from serving as both CEO and chairman to chairman of the board and chief financial officer. The leadership change comes as the New York-based biotechnology company enters a new stage of growth following the completion of a Series B financing and ahead of the planned Phase 2 clinical trial of Illuminare-1 (rizedisben) in breast reconstruction.
The appointment reflects the company’s shift from early-stage research toward later-stage clinical development, where commercialization strategy, regulatory execution and industry partnerships become increasingly important. Longstreet brings three decades of experience across the pharmaceutical, biotechnology and medical technology sectors, including leadership roles spanning product development, clinical programs and global commercialization.
He began his career at Schering-Plough and Merck & Co. before holding executive positions at Exolvo Biosciences, ChromeX Therapeutics, CorriXR Therapeutics and Orexigen Therapeutics. During his career, he has managed organizations with more than 2,000 employees while also helping build emerging biotech and medtech companies from the ground up.
“On behalf of the Board of Directors, I am delighted to welcome Brian to Illuminare at this pivotal juncture in our clinical journey,” Greenblatt said. “Brian’s exceptional track record of driving strategic growth and steering novel therapies through late-stage clinical development and commercialization makes him the ideal leader to guide the Company.”
Greenblatt said the leadership transition aligns with Illuminare’s evolution into a more mature clinical-stage organization and will support efforts to maximize the value of its product pipeline for both patients and shareholders.
Illuminare’s lead product candidate, Illuminare-1 (rizedisben), is a small-molecule imaging agent designed to improve intraoperative visualization of nerves, helping surgeons identify critical anatomy during procedures and reduce the risk of unintended nerve injury. The technology addresses a longstanding challenge in surgery, where nerve damage can result in significant postoperative complications and long-term functional impairment.
The company plans to begin a Phase 2 clinical trial evaluating Illuminare-1 in breast reconstruction following encouraging results from its Phase 1 study conducted at Memorial Sloan Kettering Cancer Center. According to the company, the first-in-human trial demonstrated a favorable safety profile, pharmacokinetics and improved visualization, delineation and identification of nerves during robot-assisted laparoscopic radical prostatectomy. Results from the study were published in JAMA Surgery in July 2025.
“I am honored to join the talented team at Illuminare Bio at such a transformative period for the company,” Longstreet said. “The preclinical and clinical data generated to date for Illuminare-1 (rizedisben) are very encouraging.” He added that his priorities include accelerating clinical development, expanding the company’s pipeline, establishing strategic industry partnerships and advancing its first product toward commercialization.
The leadership transition comes as surgical imaging technologies attract growing attention across the medical device and biotechnology sectors. Innovations that improve surgical precision and reduce procedure-related complications have become an important area of investment, particularly as healthcare systems seek technologies that can improve patient outcomes while lowering downstream costs.
With fresh capital from its recent Series B financing and a new chief executive with extensive commercialization experience, Illuminare Biotechnologies is positioning itself for the next phase of clinical and corporate development as it advances its nerve visualization platform toward later-stage trials and potential market entry.